A multicenter, placebo-controlled, double-blind, two-phase crossover study of Nasalfent (fentanyl citrate nasal spray) in the treatment of breakthrough cancer pain (BTCP) in subjects taking regular opioid therapy.
Phase of Trial: Phase III
Latest Information Update: 24 Jan 2012
At a glance
- Drugs Fentanyl (Primary)
- Indications Cancer pain
- Focus Registrational; Therapeutic Use
- 04 Oct 2010 Results have been published in Pain, according to an Archimedes Pharma media release.
- 25 Jun 2010 The Committee for Human Medicinal Products (CHMP) has recommended the approval of fentanyl based on three phase III trials including this trial.
- 05 Oct 2009 Additional lead trial investigator (Gupta R) added as reported by New Jersey Cancer Trial Connect record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History